H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Apollomics to $17 from $18 and keeps a Buy rating on the shares. The analyst sees significant potential upside for vebreltinib and near-term data catalysts for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLM: